Dysregulation of β-catenin is an Independent Predictor of Oncologic Outcomes in Patients with Clear Cell Renal Cell Carcinoma
Overview
Authors
Affiliations
Purpose: Epithelial-to-mesenchymal transition is thought to have a crucial role in cancer progression and metastatic egress. We evaluated the association of β-catenin, an important mediator of epithelial-to-mesenchymal transition, with pathological parameters and oncologic outcomes in patients with clear cell renal cell carcinoma.
Materials And Methods: Immunohistochemical staining was performed for β-catenin on tissue microarrays of patients with nonmetastatic clear cell renal cell carcinoma. Membranous and cytoplasmic expression patterns were assessed separately. β-Catenin was considered dysregulated if membranous as well as cytoplasmic expression was abnormal. Groups were compared based on normal vs dysregulated β-catenin. Survival probabilities were assessed by the Kaplan-Meier method. Cox proportional hazard models were used to identify predictors of oncologic outcomes.
Results: Included in the study were 406 patients with a median followup of 58 months. Of the patients 52 (12.8%) and 25 (6.2%) experienced recurrence and died of clear cell renal cell carcinoma, respectively. β-Catenin was dysregulated in 70 patients (17.2%). Dysregulation was uniformly associated with adverse pathological features, including advanced T stage, larger tumor diameter, nodal positivity, higher Fuhrman grade, tumor thrombus, sarcomatoid features, necrosis and lymphovascular invasion (each p<0.001). Patients with dysregulated β-catenin had inferior recurrence-free and cancer specific survival (each p<0.001). On multivariate analysis adjusting for tumor stage, nodal status and grade dysregulation was an independent predictor of recurrence-free and cancer specific survival (HR 2.2, 95% CI 1.2-3.9, p=0.008 and HR 2.4, 95% CI 1.1-5.6, p=0.044, respectively).
Conclusions: Dysregulation of β-catenin may be an important phenomenon in clear cell renal cell carcinoma carcinogenesis. These findings support further study of β-catenin, and systematic assessment of β-catenin and epithelial-to-mesenchymal transition in clear cell renal cell carcinoma.
A protein-lipid complex that detoxifies free fatty acids.
Cui S, Ye J Bioessays. 2022; 45(3):e2200210.
PMID: 36585363 PMC: 9974861. DOI: 10.1002/bies.202200210.
Song X, Liu J, Liu B, Piao C, Kong C, Li Z Cancer Med. 2022; 12(5):5764-5780.
PMID: 36200301 PMC: 10028032. DOI: 10.1002/cam4.5326.
Intratumoral Resolution of Driver Gene Mutation Heterogeneity in Renal Cancer Using Deep Learning.
Acosta P, Panwar V, Jarmale V, Christie A, Jasti J, Margulis V Cancer Res. 2022; 82(15):2792-2806.
PMID: 35654752 PMC: 9373732. DOI: 10.1158/0008-5472.CAN-21-2318.
Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma.
Petitprez F, Ayadi M, De Reynies A, Fridman W, Sautes-Fridman C, Job S Front Oncol. 2021; 11:643065.
PMID: 33996558 PMC: 8113694. DOI: 10.3389/fonc.2021.643065.
Kundu A, Sen A, Choudhury S, Mandal T, Guha D, Lahiry S Med Pharm Rep. 2021; 94(1):65-72.
PMID: 33629051 PMC: 7880061. DOI: 10.15386/mpr-1767.